Super Bowl, Hers and Hims
Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results